Search Results

October 2022 Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived Great success has been reached with therapies based on the GLP-1 receptor monoagonism; therefore, a logical

Nevertheless, researchers have a host of new technologies at their disposal to develop targeted therapies

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at

August 2022 "Chemokines, a subgroup of cytokines along with their receptors, are involved in various biologic processes and regulation of a wide range of immune responses in different physiologic and pathologic states such as tissue repair, infection, and inflammation. C-X-C motif chemokine receptor 4 (CXCR4), a G-protein-coupled receptor (GPCR), has one identified natural ligand termed stromal-derived factor-1(SDF-1 or CXCL12). Evidence demonstrated that the ligation of SDF-1 to CXCR4 initiates several intracellular signaling pathways, regulating cell proliferation, survival, chemotaxis, migration, angiogenesis, adhesion, as well as bone marrow (BM)-resident cells homing and mobilization. Additionally, CXCR4 is expressed by tumor cells in blood malignancies and solid tumors." Read more at the source #DrGPCR #GPCR #IndustryNews

December 2021 "Early-stage studies of COVID-19 treatments from the likes of Vir Biotechnology Inc. and Trevena Inc. could offer potential new weapons against omicron and future viral variants. The omicron strain of the virus was first identified in South Africa in early November, and an existing treatment has already shown positive results in the lab. While vaccine-makers race to test their shots against the variant, the monoclonal antibody sotrovimab from Vir and partner GlaxoSmithKline PLC posted results Dec. 7 demonstrating activity against the omicron spike protein. Sotrovimab is the first monoclonal antibody showing preclinical efficacy against all COVID-19 variants, including the delta and omicron mutations, Vir CEO George Scangos said on a Dec. 7 call with analysts." Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 "For decades, glioblastoma multiforme (GBM), a type of the most lethal brain tumor, has remained a formidable challenge in terms of its treatment. Recently, many novel discoveries have underlined the regulatory roles of neurotransmitters in the microenvironment both physiologically and pathologically. By targeting the receptors synaptically or non-synaptically, neurotransmitters activate multiple signaling pathways. Significantly, many ligands acting on neurotransmitter receptors have shown great potential for inhibiting GBM growth and development, requiring further research. Here, we provide an overview of the most novel advances concerning the role of neurotransmitters in the normal neural and the GBM microenvironments, and discuss potential targeted drugs used for GBM treatment." Read more at the source #DrGPCR #GPCR #IndustryNews

PAR-expressing tumors but also for treating EGFR/erbB-expressing tumors in cases of resistance to traditional therapies Overall, our studies are expected to allocate new targets for cancer therapy.

breast cancer (TNBC) is a particularly aggressive and heterogeneous disease with few effective targeted therapies into GPER-mediated estrogen carcinogenesis in TNBC, thus providing a potential strategy for endocrine therapy

, Inc. a pre-clinical stage biotechnology company transforming the discovery of novel GPCR-targeted therapies

With the United States Food and Drug Administration's designation of psilocybin as a "Breakthrough Therapy

distributed to support third party research, but the group also does its own research into promising therapy

By understanding how different SNPs affect β2AR function, it becomes possible to tailor therapies based signalling, this research provides a foundation for the development of more targeted and effective drug therapies

with potential applications in chemical biology: a mini-review YAP/TAZ: Molecular pathway and disease therapy Update for Second Quarter and First Half of 2023 Novo Nordisk to acquire Inversago Pharma to develop new therapies

cancer, and provided a small molecule inhibitor GA directly and selectively targeting GPR108 for cancer therapy

on data related to GPCR implicated in immunoresistance, to develop first-in class innovative cancer therapies

Inhibiting overactive SHH signaling may be a potential neuroprotective therapy for sPD."

Proteins Indicates Biased Signal Transduction Pathways Activation of a GPCR, ORL1 receptor: A novel therapy Confo Therapeutics Announces EUR 60M Series B Financing to Advance a Pipeline of Novel GPCR-Modulating Therapies

receptors to initiate new drug-screening strategies and targeted delivery of safe and effective GBM therapies

Orthosteric and allosteric antagonists of C5aR1 are a novel strategy for anti-inflammatory therapies.

Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy

have been evaluated as rhodopsin modulators to be considered as leads for the development of novel therapies

the modification of the chemical structure of the lead compounds to improve potency and selectivity, thereby It also helps in combination therapy strategies, where drugs are designed to target multiple sites or This can guide the development of more personalised therapies tailored to the genetic makeup of individual

new avenues for understanding drug tolerance and resistance, particularly in the context of opioid therapies

G-protein coupled receptors (GPCRs) have been largely targeted in a wide range of diseases, but few therapies

Currently-approved treatments have improved patient outcomes, but therapies to stop or reverse HF are

optogenetically functionalized Drosophila dopamine receptors Targeting CB2R in astrocytes for Parkinson's disease therapy Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

targeting chemokine receptors: maraviroc, an allosteric and reversible inhibitor of the CCR5 used in HIV therapy ; and the small molecule plerixafor, a CXCR4 antagonist used in cancer therapy (Isberg et al. 2016).

Structural characterization of biologics, such as vaccines, viral vectors, and gene therapy agents, has